Sacituzumab tirumotecan: severe toxicities cluster in the first two cycles

Design

Post hoc safety analysis of a randomised phase 3 trial (OptiTROP-Breast01)

Population

262 patients with previously treated metastatic TNBC (130 sac-TMT, 132 physician's choice)

Primary outcome

Timing, pattern and recovery of key adverse events

Effect

Grade ≥3 key AEs mostly in cycles 1–2; recovery to grade ≤2 typically within 14 days

A post hoc safety analysis of the randomised OptiTROP-Breast01 trial, published in Breast Cancer Research on 28 September, looked in detail at 130 patients with previously treated metastatic triple-negative breast cancer given sacituzumab tirumotecan (sac-TMT), a TROP2 antibody-drug conjugate approved in China, and 132 given treatment of physician's choice.

The key toxicities — anaemia, neutropenia, thrombocytopenia and stomatitis — reached grade 3 or higher mostly within the first two cycles. Most patients recovered to grade 2 or lower, typically within 14 days. Efficacy looked similar whether the dose was reduced early, reduced later or not at all, and among patients treated for more than seven months, treatment-related adverse events became less frequent over time.

The practical message applies to TROP2 conjugates generally: front-load monitoring, anticipate stomatitis and cytopenias, and use dose modification rather than stopping. The efficacy comparison by dose reduction is exploratory and subject to selection. Sac-TMT's regulatory status in India is not known.

• Monitor blood counts and the mouth closely through the first two cycles of a TROP2 antibody-drug conjugate.
• Start stomatitis prevention and mouth care from cycle one.
• Use dose reduction for severe toxicity; in this analysis it did not appear to reduce efficacy.
• Expect most grade 3 or higher toxicities to recover within about two weeks.

Why it matters

Knowing when toxicity peaks lets teams schedule monitoring and support where it is needed.

Don't overread it

Post hoc and exploratory; it does not prove that dose reduction preserves efficacy.

The statistics, in plain English

This is a post hoc description of adverse events, not a new efficacy result. The finding that efficacy was similar with and without dose reduction compares groups that were not randomised, so patients who needed reductions may differ in other ways.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.